Amit Goyal, MD | tctmd.com
Dec 30, 2024 · Amit Goyal, MD, is a structural interventional cardiologist and Director of the CICU at the Dallas VA Medical Center, Editor-in-Chief of US Cardiology Review, and co-founder —with Daniel Ambinder, MD— of CardioNerds.. In the latter capacity, he leads the overarching curriculum and has designed the CardioNerds Clinical Trials Network, CardioNerds Academy, and Medical Journalism programs.
The ARTIST Study and the Future of TAVR for Aortic Regurgitation
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
TCTMD - tctmd.com
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
ECLIPSE: Orbital Atherectomy No Better Than Balloon Angioplasty …
Oct 29, 2024 · Interventional cardiologists have many tools at their fingertips to address calcified lesions—which are known to be among the most complex—including angioplasty with conventional balloons as well as cutting and scoring balloons, orbital and rotational atherectomy, and lithotripsy. These new data indicate that the simplest—and notably the cheapest—approach might be the most reasonable.
TCT 2024 - TCTMD.com
Oct 27, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
TCTMD Login - tctmd.com
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR …
Nov 18, 2024 · CHICAGO, IL—Two new drugs targeting lipoprotein(a)—one a small interfering RNA (siRNA), the other an oral agent that prevents its formation—both showed positive results in early phase II studies, with the therapies reducing Lp(a) by roughly 80% over extended follow-up.
AI Poised to Change the Landscape of Echocardiography
Nov 19, 2024 · CHICAGO, IL—Artificial intelligence (AI) has already changed the way echocardiography is practiced, but two new studies presented here at the American Heart Association 2024 Scientific Sessions show its potential to transform the landscape even further.
QFR No Match for FFR in Guiding Revascularizations: FAVOR III …
Oct 30, 2024 · WASHINGTON, DC—As a guide for deciding whether to revascularize patients with intermediate coronary stenoses, quantitative flow ratio (QFR) isn’t able to match fractional flow reserve (FFR) in terms of 12-month clinical outcomes, data from the large, randomized, FAVOR III Europe trial show.
Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial …
Oct 29, 2024 · WASHINGTON, DC—The routine use of colchicine, an anti-inflammatory agent with a challenging side-effect profile, fails to reduce the risk of major adverse cardiovascular events when used in patients treated with PCI after acute myocardial infarction, results from the CLEAR SYNERGY (OASIS 9) trial show.